Named Bioactive Compounds · Compound
Hesperetin
Strong Evidenceflavonoid
Hermetica Superfood Encyclopedia
Hesperetin is a citrus flavonoid that acts as the bioactive aglycone form of hesperidin, demonstrating enhanced cellular absorption. This compound modulates lipid metabolism and cellular antioxidant pathways through NF-κB inhibition and HMG-CoA reductase regulation.
Hesperetin is the aglycone form of hesperidin, a flavanone compound abundant in citrus fruits including sweet oranges (Citrus sinensis), lemons, grapefruits, and tangerines. It is typically obtained through the hydrolysis of hesperidin extracted from the white inner layer of citrus peels, though it can also be directly isolated from plants like Brickellia vernicosa or Prunus species.
The research dossier indicates that no specific human clinical trials, randomized controlled trials (RCTs), or meta-analyses for hesperetin were found. The available evidence appears to be primarily preclinical or based on general nutraceutical properties inferred from citrus sources.
No clinically studied dosage ranges for hesperetin have been established in human trials according to the available research. Forms (extract, powder, standardized) and standardization details are not specified in the literature. Consult a healthcare provider before starting any new supplement.
Hesperetin (molecular formula: C₁₆H₁₄O₆; MW: 302.28 g/mol) is a flavanone aglycone, not a food consumed for macronutrient value. It is the aglycone (sugar-free) form of hesperidin, released in the colon by bacterial β-glucosidases (primarily Bifidobacterium and Lactobacillus species) cleaving the rutinoside moiety. Key bioactive characteristics: • Classification: Flavanone subclass of flavonoids; 4'-methoxy-5,7-dihydroxyflavanone. • Natural concentrations in food sources: Found indirectly via hesperidin in sweet orange peel (~28–42 mg hesperidin/g dry weight), lemon peel (~15–25 mg/g dry weight), grapefruit juice (~1–5 mg/100 mL as hesperidin equivalents), and whole oranges (~20–40 mg hesperidin per fruit). Free hesperetin in intact fruit is negligible (<0.5 mg/100 g); it is generated almost entirely by gut microbial deglycosylation. • Bioavailability: Oral bioavailability of hesperetin from hesperidin is estimated at ~3–6% in humans (Tmax ~4–7 hours reflecting colonic liberation). When administered as hesperetin-7-O-glucoside (a more soluble precursor), absorption is faster (Tmax ~1–2 hours) and peak plasma concentrations are ~3–5× higher than from hesperidin. Plasma concentrations typically reach 0.1–2.2 µmol/L after single doses of 130–500 mg hesperidin equivalents. • Phase II metabolism: Extensively conjugated in intestinal epithelium and liver to hesperetin-7-O-glucuronide (major circulating metabolite, ~70–87% of plasma flavanone pool), hesperetin-3'-O-glucuronide, and hesperetin sulfates. Free (unconjugated) hesperetin in plasma is <5% of total. • Key functional groups: Two phenolic hydroxyl groups (C-5, C-7) and one methoxy group (C-4') contribute to antioxidant capacity (ORAC ~2.5–3.0 µmol Trolox equivalents/µmol). The 4'-OCH₃ reduces radical-scavenging potency relative to eriodictyol (the fully hydroxylated analog) but enhances lipophilicity (log P ~2.6) and membrane permeability. • Micronutrient/macronutrient content: Not applicable — hesperetin is a phytochemical, not a source of vitamins, minerals, protein, fiber, or caloric energy at physiologically relevant intake levels. • Solubility: Poorly water-soluble (~12–18 µg/mL at 25 °C, pH 7.0); solubility increases at alkaline pH due to phenolate formation. Lipid-based delivery systems, cyclodextrin complexation, and nanoformulations have been shown to improve solubility 5–20×. • Interactions with nutrients: In vitro evidence suggests hesperetin can chelate iron (Fe²⁺/Fe³⁺) and copper (Cu²⁺) at micromolar concentrations, potentially modulating metal-catalyzed oxidation but unlikely to affect mineral absorption at dietary intakes. May modulate P-glycoprotein and CYP3A4 activity at high concentrations (IC₅₀ ~10–50 µmol/L in vitro), with theoretical but clinically unconfirmed effects on drug/nutrient bioavailability.
Hesperetin inhibits HMG-CoA reductase enzyme activity, potentially reducing cholesterol biosynthesis in hepatic cells. The compound also suppresses NF-κB inflammatory signaling pathways and activates Nrf2-mediated antioxidant response elements. Additionally, hesperetin modulates cytochrome P450 enzymes and may influence AMPK activation for metabolic regulation.
Current clinical evidence for hesperetin remains limited, with most research focused on hesperidin rather than the aglycone form. Preliminary in vitro studies suggest cholesterol-lowering potential through enzyme inhibition, but human trials are lacking. Cell culture studies indicate anti-proliferative effects against various cancer cell lines, though these findings have not been validated in clinical populations. The bioavailability advantage over hesperidin has been demonstrated in pharmacokinetic studies, but therapeutic outcomes require further investigation.
Hesperetin appears generally well-tolerated based on its presence in citrus fruits, though isolated supplement safety data is limited. Potential drug interactions may occur with medications metabolized by cytochrome P450 enzymes, particularly CYP3A4 substrates. Individuals taking cholesterol medications should consult healthcare providers due to potential additive effects on lipid metabolism. Pregnancy and breastfeeding safety has not been established for concentrated hesperetin supplements beyond normal dietary intake levels.
